HTG plans to list its shares on the Nasdaq and is the 11th firm this year in the MDx/omics tools space to either go public or file for an IPO.
Pressures, including reimbursements and flat NIH funding, continued to dampen M&A in the past year, but one expert said that the picture may be brighter than it appears.
In an SEC document, the company called current market conditions for an IPO unattractive.
The firm offers a portfolio of genetic tests to help clinicians tailor treatments for patients suffering from cardiovascular disease, neuropsychiatric disorders, and pain.
The company makes tests with rapid time-to-results intended for high-volume hospital and pathology labs using its proprietary diagnostic technology, 3Base.
Melanoma test development firm DermTech is pulling its proposed initial public offering.
NEW YORK (GenomeWeb) — Molecular diagnostics firm Great Basin Scientific has priced a planned initial public offering of 1.15 million units, with each unit consisting of one share of common stock and one Series A warrant.
NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.
NEW YORK (GenomeWeb) – Autoimmune rheumatic disease diagnostics firm Exagen Diagnostics filed a preliminary prospectus on Friday for an initial public offering of up to $69 million.
NEW YORK (GenomeWeb) – DermTech reported recently that it recorded $46,000 in revenues for the first six months of the year, up from none a year ago.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.